Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track LONA with free AI briefings, catalyst countdowns, and dilution alerts.

LONA · LeonaBio, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$51.1M Cash on Hand
8.1mo Cash Runway
Follow LONA by email Get an email when LONA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about LONA, unsubscribe in one click. Privacy

📣 What LONA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Fosgonimeton Sodium (ATH-1017) Alzheimer Disease Phase 2/3 · NCT04488419 Completed
[14C]-Fosgonimeton Healthy Volunteers Phase 1 · NCT05511558 Completed
ATH-1020 Healthy Volunteers Phase 1 · NCT05169671 Completed
ATH-1105 Healthy Volunteers Phase 1 · NCT06432647 Completed

Also used in these trials (approved or third-party drugs, not LONA's own candidates): Abemaciclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

LONA holds $51.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $18.9M/quarter from operations, an estimated runway of 8.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 85 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when LONA files for a raise →

👥 Who Owns LONA

Insiders 27.6% Other 5%+ holders 49.8% Institutions (54 holders) 22.6% Public and other holders 0%
HolderTypeShares% of sharesAs of
David J. Portman
10% owner
Insider 3,149,470 24.09% 2026-10-26
Sermonix Pharmaceuticals, Inc. 5%+ holder (13D) 3,149,470 24.09% 2026-10-26
Joseph Edelman 5%+ holder (13D) 1,869,050 14.29% 2025-12-23
Anders Hove 5%+ holder (13G) 1,492,521 11.41% 2026-08-18
ADAR1 Capital Management, LLC Institution (13G, 5%+) 727,481 5.56% 2026-03-31
Great Point Partners, LLC Institution (13G, 5%+) 474,345 3.63% 2026-10-28
PERCEPTIVE ADVISORS LLC
Director, 10% owner · +3.78M options
Insider 329,756 2.52% 2026-10-26
Mark James Litton
PRESIDENT and CEO, Director · +750,000 options
Insider 59,894 0.46% 2026-03-03
Kevin Church
CHIEF SCIENTIFIC OFFICER · +300,000 options
Insider 25,178 0.19% 2026-03-03
Mark Worthington
GENERAL COUNSEL and CCO · +300,000 options
Insider 18,376 0.14% 2026-03-03
Martin Javier San
CHIEF MEDICAL OFFICER · +350,000 options
Insider 15,887 0.12% 2026-03-03
Robert Renninger
CHIEF FINANCIAL OFFICER · +300,000 options
Insider 15,851 0.12% 2026-03-03

Share count 13,076,348 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full LONA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for LONA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.